C7A.012
Malignant carcinoid tumor of the ileum
Clinical Classification Guidelines
Medical Intelligence & Overview
A malignant carcinoid tumor of the ileum is a type of cancer that originates in the neuroendocrine cells of the ileum, which is the last part of the small intestine. These tumors are considered rare but can be aggressive, with potential to spread beyond the initial site. Recognizing this condition early is important for management and treatment options. This article provides an accessible overview of malignant carcinoid tumors of the ileum, including their causes, symptoms, diagnosis, and treatments.
Causes & Symptoms
Clinical Causes: Genetic mutations that affect cell growth and division Family history of neuroendocrine tumors Possible association with other hereditary syndromes such as Multiple Endocrine Neoplasia type 1 (MEN1) Environmental factors, though specific triggers are not well-established
Key Symptoms: Abdominal pain or discomfort Changes in bowel habits, such as diarrhea or constipation Unexplained weight loss Facial flushing or skin redness, especially after eating or drinking alcohol Presence of a palpable abdominal mass Symptoms related to hormone production if the tumor secretes bioactive substances Carcinoid syndrome symptoms, including wheezing and rapid heartbeat
Diagnostic & Treatment
Diagnosis Path: Diagnosing a malignant carcinoid tumor of the ileum involves various tests: - Endoscopy: Visual examination of the gastrointestinal tract - Imaging tests: CT scan, MRI, or somatostatin receptor scintigraphy to identify tumor location and spread - Biopsy: Taking a tissue sample for microscopic examination - Blood and urine tests: Measuring levels of hormones and other substances secreted by the tumor, such as serotonin or chromogranin A - Surgical exploration: Sometimes necessary for definitive diagnosis and staging
Treatment Protocols: Treatment options for a malignant carcinoid tumor of the ileum focus on removing the tumor and managing symptoms. These include: - Surgery: Primary approach involving removal of the tumor and affected tissue; may include resection of part of the ileum - Medications: Somatostatin analogs (like octreotide and lanreotide) to control hormone secretion and tumor growth - Chemotherapy: Used in advanced cases or when surgery isn’t possible - Targeted therapy: Emerging treatments that focus on specific molecules involved in tumor growth - Follow-up care: Regular monitoring through imaging and blood tests to detect recurrence or metastasis
Clinical Advice & FAQs
Billing Guidance
Is C7A.012 a billable ICD-10 code?
Yes, C7A.012 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C7A.012?
Clinical documentation must specify the nature of Malignant carcinoid tumor of the ileum and any associated comorbidities for accurate reporting.
Cite this Clinical Reference